Aligos Therapeutics Stock Market Value
| ALGS Stock | USD 6.68 0.23 3.33% |
| Symbol | Aligos |
Is there potential for Biotechnology market expansion? Will Aligos introduce new products? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Aligos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Aligos Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Aligos Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Aligos Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aligos Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Aligos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Aligos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aligos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aligos Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Aligos Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Aligos Therapeutics or generate 0.0% return on investment in Aligos Therapeutics over 90 days. Aligos Therapeutics is related to or competes with Kezar Life, X4 Pharmaceuticals, Tempest Therapeutics, Barinthus Biotherapeutics, OnKure Therapeutics, CEL SCI, and INmune Bio. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address ... More
Aligos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aligos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aligos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 10.16 |
Aligos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aligos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aligos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aligos Therapeutics historical prices to predict the future Aligos Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.31) |
Aligos Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 4.38 | |||
| Coefficient Of Variation | (3,056) | |||
| Standard Deviation | 5.66 | |||
| Variance | 32.08 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.20) | |||
| Potential Upside | 10.16 | |||
| Skewness | 0.433 | |||
| Kurtosis | 0.3546 |
Aligos Therapeutics Backtested Returns
Aligos Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0327, which signifies that the company had a -0.0327 % return per unit of risk over the last 3 months. Aligos Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aligos Therapeutics' Standard Deviation of 5.66, mean deviation of 4.38, and Risk Adjusted Performance of (0.02) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.62, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aligos Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aligos Therapeutics is expected to be smaller as well. At this point, Aligos Therapeutics has a negative expected return of -0.19%. Please make sure to confirm Aligos Therapeutics' treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if Aligos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Aligos Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Aligos Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aligos Therapeutics price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Aligos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.77 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.